LRMRLarimar Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$172M
- 90% YoY
- Market cap
- $257M
- Employees
- —
- Net debt / EBITDA
- —
- −$78M net debt
- AI in 10-K
- 1.9
- mentions per 10K words
Takeover score 0 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo$3M medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo—Any vote under 80% support
Buyer economics 0 of 4
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo1.9 per 10K words · 53rd pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedNo$257M market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo$26M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$50M | −$37M | −$42M | −$91M | −$172M | 90% |
| Net income | −$51M | −$35M | −$37M | −$81M | −$166M | 106% |
| Operating cash flow | −$42M | −$28M | −$33M | −$71M | −$113M | 60% |
| Capex | $333K | $100K | $164K | $515K | $91K | 82% |
| Stock-based comp | $5M | $7M | $8M | $9M | $7M | 20% |
Deal filings
| Filed | Form | Acquirer | Price | Premium |
|---|---|---|---|---|
| Apr 29, 2020 | DEFM14A | Chondrial Therapeutics, Inc. | $645.51 | — |
| Mar 6, 2020 | PREM14A | Chondrial Therapeutics, Inc. | $1.18 | 64.55% |
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Mar 2, 2026 | Flynn James E | SCHEDULE 13D/A | 34.4% | Passive |
| Jul 31, 2025 | Flynn James E | SCHEDULE 13D/A | 35.8% | Passive |
| Mar 15, 2024 | Flynn James E | SC 13D/A | 33.3% | Passive |
| Feb 16, 2024 | Flynn James E | SC 13D/A | 34.8% | Passive |
| Feb 15, 2024 | Flynn James E | SC 13D/A | 10.8% | Passive |
| Mar 17, 2023 | Flynn James E | SC 13D/A | 10.9% | Passive |
| Sep 16, 2022 | Flynn James E | SC 13D/A | 11.8% | Passive |
| Jul 2, 2021 | Flynn James E | SC 13D/A | 11.0% | Passive |
| May 26, 2021 | Flynn James E | SC 13D/A | 33.5% | Passive |
| May 21, 2021 | Flynn James E | SC 13D/A | 11.2% | Passive |
Insider trading
- Open-market buys, 12 mo
- $26M · 8
- Open-market sells, 12 mo
- $0 · 0
- Net
- $26M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $4M | $2M | 36 | — |
| FY2024 | $3M | $2M | 36 | — |
| FY2023 | $3M | $3M | 42 | — |